Overview

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

A phase II, multi-center (approximately 10 sites in Israel), randomized, placebo-controlled, dose- finding study comparing the efficacy, safety and tolerability of different dosing regimens of Allocetra-OTS, in up to 160 adult sepsis patients with organ sysfunction.

Phase:

Phase 2

Details

Lead Sponsor:

Enlivex Therapeutics Ltd.

Collaborator:

Cato Research